Active Ingredient(s): Pegaptanib
FDA Approved: * December 17, 2004
Pharm Company: * EYETECH PHARMS
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Macugen Overview

Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD).[2] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. [3] ...

Read more Macugen Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Macugen Forums: RSS Feed

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 0.3mg/0.09ml, eq 0.3mg acid/0.09ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Macugen: (1 result)

Sorted by National Drug Code
  • 68782-001 Macugen 3.47 mg/ml Intravitreal Injection, Solution by Eyetech Inc.

Other drugs which contain Pegaptanib or a similar ingredient: (1 result)

Related Macugen Topics:

macugen lucentis
masculen degeneration...